IN2014DN09640A - - Google Patents

Info

Publication number
IN2014DN09640A
IN2014DN09640A IN9640DEN2014A IN2014DN09640A IN 2014DN09640 A IN2014DN09640 A IN 2014DN09640A IN 9640DEN2014 A IN9640DEN2014 A IN 9640DEN2014A IN 2014DN09640 A IN2014DN09640 A IN 2014DN09640A
Authority
IN
India
Prior art keywords
protein tyrosine
tyrosine phosphatase
disorder
ptp
precursors
Prior art date
Application number
Inventor
Michel Therien
Yves Leblanc
Yongxin Han
Original Assignee
Kaneq Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneq Pharma Inc filed Critical Kaneq Pharma Inc
Publication of IN2014DN09640A publication Critical patent/IN2014DN09640A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4021—Esters of aromatic acids (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Fused aromatic phosphonates of structural formula I are precursors to inhibitors of protein tyrosine phosphatase- 1B, (PTP 1B). The compounds of the present invention are therefore useful for the treatment in a mammal of a disorder , condition , or disease responsive to inhibition of protein tyrosine phosphatase 1B including Type 2 diabetes, insulin resistance , a lipid disorder obesity , Metabolic Syndrome , and cancer.
IN9640DEN2014 2012-04-16 2013-04-16 IN2014DN09640A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261624572P 2012-04-16 2012-04-16
PCT/CA2013/000364 WO2013155600A1 (en) 2012-04-16 2013-04-16 Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN09640A true IN2014DN09640A (en) 2015-07-31

Family

ID=49382741

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9640DEN2014 IN2014DN09640A (en) 2012-04-16 2013-04-16

Country Status (11)

Country Link
US (1) US20150057220A1 (en)
EP (1) EP2838906A4 (en)
JP (1) JP2015519309A (en)
KR (1) KR20140145624A (en)
CN (1) CN104411710A (en)
AU (1) AU2013248880A1 (en)
CA (1) CA2870488A1 (en)
IL (1) IL235081A0 (en)
IN (1) IN2014DN09640A (en)
MX (1) MX2014012465A (en)
WO (1) WO2013155600A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023220833A1 (en) * 2022-05-19 2023-11-23 Kanyr Pharma Inc. Combined inhibition of tyrosine phosphatases tcptp and ptp1b and pd-1 blockage immunotherapy in the treatment of cancer

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
AR008789A1 (en) 1996-07-31 2000-02-23 Bayer Corp PIRIDINES AND SUBSTITUTED BIPHENYLS
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
EP0970095B1 (en) 1997-03-07 2003-10-29 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
JP2003514508A (en) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ Glucagon antagonist / adverse agent
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
DE69910045T2 (en) 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego NEW HETEROAROMATIC FRUCTOSE 1,6-BISPHOSPHATASE INHIBITORS
JP2002534512A (en) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ Non-peptide GLP-1 agonist
DE60012721T4 (en) 1999-03-29 2010-09-09 Uutech Ltd., Coleraine ANALOGUE OF THE MAGENTA-INHIBITING PEPTIDE AND ITS USE IN THE TREATMENT OF DIABETES
AU4055400A (en) 1999-04-02 2000-10-23 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
EP1183229B1 (en) 1999-05-17 2005-10-26 Novo Nordisk A/S Glucagon antagonists/inverse agonists
CA2379604A1 (en) 1999-09-28 2001-04-05 Bayer Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
CA2401984A1 (en) 2000-03-22 2001-09-27 Merck Frosst Canada Inc. Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
JP2004513076A (en) 2000-07-25 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド N-substituted indoles useful in the treatment of diabetes
US6852738B2 (en) 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
SE0102764D0 (en) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AR040241A1 (en) 2002-06-10 2005-03-23 Merck & Co Inc INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGRENASE 1 FOR THE TREATMENT OF DIABETES OBESITY AND DISLIPIDEMIA
EP1546142A4 (en) 2002-08-29 2007-10-17 Merck & Co Inc Indoles having anti-diabetic activity
NZ538031A (en) 2002-08-29 2007-10-26 Merck & Co Inc Indoles having anti-diabetic activity
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Triazole Derivatives As Inhibitors Of 11-Beta -Hydroxysteriod Dehydrogenase-1
JP2007504285A (en) 2003-01-17 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド N-cyclohexylaminocarbonylbenzenesulfonamide derivative
JP4400563B2 (en) 2003-02-13 2010-01-20 萬有製薬株式会社 New 2-pyridinecarboxamide derivatives
CN101712657A (en) 2003-02-26 2010-05-26 万有制药株式会社 heteroarylcarbamoylbenzene derivative
DK1891105T3 (en) 2005-06-13 2012-07-16 Imp Innovations Ltd New compounds and their effects on eating behavior
WO2007100535A2 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
ATE516300T1 (en) 2006-03-20 2011-07-15 Merck Sharp & Dohme NEUROMEDIN-U RECEPTOR AGONISTS AND THEIR USE
AR061930A1 (en) 2006-07-18 2008-10-01 Centocor Inc MIMETICBODIES OF GLP-1 HUMANS, COMPOSITIONS, METHODS AND USES
ES2547386T3 (en) 2007-01-26 2015-10-05 Kaneq Pharma Inc. Condensed aromatic PTP-1B inhibitors
KR20090119876A (en) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon/glp-1 receptor co-agonists
EP2170883A1 (en) 2007-06-28 2010-04-07 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
EP2178537A4 (en) 2007-07-19 2011-08-17 Merck Sharp & Dohme Beta carboline derivatives as antidiabetic compounds
US20110301079A1 (en) 2007-09-21 2011-12-08 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Neuromedin u receptor agonists and uses thereof

Also Published As

Publication number Publication date
CA2870488A1 (en) 2013-10-24
AU2013248880A1 (en) 2014-11-06
US20150057220A1 (en) 2015-02-26
CN104411710A (en) 2015-03-11
KR20140145624A (en) 2014-12-23
IL235081A0 (en) 2014-12-31
EP2838906A4 (en) 2015-07-15
MX2014012465A (en) 2015-01-12
JP2015519309A (en) 2015-07-09
EP2838906A1 (en) 2015-02-25
WO2013155600A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
DOP2017000090A (en) AMINOPIRIDILOXIPIRAZOL COMPOUNDS
CY1124928T1 (en) PYRAZOLYL QUINOXALINE KINASE INHIBITORS
CY1121114T1 (en) GLUCAGON AGONISTS / GLP-1 FOR THE TREATMENT OF OBESITY
MX2018005340A (en) Proteolysis targeting chimera compounds and methods of preparing and using same.
CY1122796T1 (en) IMPROVED PHARMACEUTICAL FORMS OF ADENOS
EP2560660A4 (en) Chemosensory receptor ligand-based therapies
PH12015502275B1 (en) Therapuetic uses of empagliflozin
MX2021011939A (en) Neuroactive compounds and methods of use thereof.
MX362190B (en) Dual glp1/gip or trigonal glp1/gip/glucagon agonists.
PH12015500688A1 (en) Exendin-4 derivatives as dual glp1/glucagon agonists
MY170713A (en) Treatment protocol of diabetes type 2
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
CO6551721A2 (en) NEW KINASE MODULATORS
BR112014026952A2 (en) aminopyrimidine pyrazole derivatives as modulators lrrk2
MX2020010004A (en) Therapeutic uses of empagliflozin.
EA201490420A1 (en) TREATMENT OF DISEASES ASSOCIATED WITH α-SUBUNITS OF POTENTIAL-DEPENDENT SODIUM CHANNELS (SCNxA) WITH THE HELP OF SMALL MOLECULES
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
MX2016008624A (en) Serine/threonine kinase inhibitors.
MX2014002159A (en) Pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
MX349254B (en) Compounds for treatment of metabolic syndrome.
FR2975600B1 (en) AGENTS FOR THE TREATMENT OF TUMORS
CO7350641A2 (en) Compounds of 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine for use in the treatment of diabetes and its associated disorders
EA201400623A1 (en) NEW 2H-INDASOLS AS ANTAGONISTS EP EPCEPTOR
UA108494C2 (en) Application(rs)-s-cyclopropyl-s-(4-{[4-{[(1r,2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pirimidine-2-il]amino}phenyl)sulfoximide for treating tumors.
CL2014001278A1 (en) Tricyclic compounds, protein kinase inhibitors cdc42 binding to protein kinase alpha (cdc42bpa or mrcka); pharmaceutical composition; and its use to treat a disease, disorder or condition selected from obesity, overweight, abnormal fat distribution or any condition or disease associated with it.